# China Montelukast Intermediate Market

> China Montelukast Intermediate Market Research Report By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.2%
- **2024:** $ 32 Million
- **2025:** $ 33.98 Million
- **2035:** $ 62 Million
- **Key Players:** Merck & Co. (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (IL), Aurobindo Pharma (IN), Cipla Ltd. (IN), Hikma Pharmaceuticals PLC (GB), Sandoz International GmbH (CH), Zydus Cadila (IN)

**Report ID:** MRFR/HC/51295-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-montelukast-intermediate-market-53056

---

## Market Summary

## **China Montelukast Intermediate Market Overview**

As per MRFR analysis, the China Montelukast Intermediate Market Size was estimated at 0.77 (USD Million) in 2023. The China Montelukast Intermediate Market Industry is expected to grow from 1.5 (USD Million) in 2024 to 2.5 (USD Million) by 2035. The China Montelukast Intermediate Market CAGR (growth rate) is expected to be around 4.753% during the forecast period (2025 - 2035).

## **Key China Montelukast Intermediate Market Trends Highlighted**

Significant trends are being driven by the growing awareness of respiratory diseases and the increasing demand for healthcare in the China Montelukast Intermediate Market. Given the increasing incidence of asthma and allergic reactions in the general population, there is a greater emphasis on the development of effective treatment options and preventive care.

The demand for effective medications, such as Montelukast intermediates, has been further accelerated by the Chinese government's dedication to enhancing healthcare access and establishing comprehensive medical insurance systems. Potential collaborations between domestic pharmaceutical companies and international firms are designed to improve research and development capabilities.

Furthermore, local manufacturers are afforded the opportunity to innovate and increase the production of Montelukast intermediates while adhering to the regulatory standards established by the National Medical Products Administration as China strives to achieve self-sufficiency in drug production. The quality assurance framework has become more robust in recent years as a result of the increased regulatory scrutiny.

Technological advancements are enabling more efficient manufacturing processes, which can enhance the overall supply chain and reduce production costs. The trend toward digital health solutions also holds potential, as telemedicine and online consultations are becoming more common. This trend is driving the need for dependable medications such as Montelukast to support patient treatment plans.

These trends are indicative of the changing landscape of the Chinese pharmaceutical industry and underscore the increasing importance of the Montelukast intermediate market within this context. Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

## **China Montelukast Intermediate Market Drivers**

### **Rising Prevalence of Asthma and Allergies in China**

The rising prevalence of asthma and allergic diseases in China is a critical driver for the China Montelukast Intermediate Market Industry. According to the Chinese Center for Disease Control and Prevention, approximately 30 million people in China have asthma, indicating a significant patient base.

With asthma rates increasing at an alarming rate of 10% annually, this positions Montelukast, an effective leukotriene receptor antagonist, as an essential treatment option in the Chinese healthcare system. Organizations such as the China National Health Commission are focusing on improving treatment regimens, leading to increased demand for Montelukast intermediates.

As the Chinese government's healthcare policies promote better allergy and asthma management, this trend is expected to fuel growth in the Montelukast Intermediate Market.

### **Government Initiatives to Enhance Respiratory Health**

China's government initiatives aimed at enhancing respiratory health are significantly impacting the China Montelukast Intermediate Market Industry. The Healthy China 2030 initiative outlines substantial investments in public health infrastructure, focusing on chronic respiratory diseases.

The initiative is expected to allocate over 28 billion USD towards respiratory health initiatives, driving demand for medications like Montelukast. As the government encourages Research and Development in pharmaceutical production, firms are likely to ramp up the synthesis of Montelukast intermediates, aligning supply with growing healthcare needs.

This boosts the overall market prospects and underlines the growing importance of effective therapeutic solutions within China's healthcare framework.

### **Growing Aging Population in China**

The increasing proportion of the aging population in China is a significant factor for the China Montelukast Intermediate Market Industry. The National Bureau of Statistics has reported that by 2040, the aging population (aged 60 and over) will exceed 400 million, accounting for nearly 30% of the total population.

This demographic trend correlates with higher incidences of chronic diseases, including respiratory conditions such as asthma and Chronic Obstructive Pulmonary Disease. As older adults face a higher risk of such illnesses, the demand for effective treatments, like Montelukast, is expected to surge.

Consequently, pharmaceutical companies are likely to increase production levels of Montelukast intermediates to meet the anticipated rise in prescription needs for managing respiratory health among older adults.

## **China Montelukast Intermediate Market Segment Insights**

### **Montelukast Intermediate Market Application Insights**

The Application segment of the China [Montelukast Intermediate Market](../../../reports/montelukast-intermediate-market-7887) plays a crucial role in addressing various respiratory and allergic conditions, thereby highlighting its importance in the healthcare landscape of the country. Among the diverse Applications of Montelukast, Asthma is a significant focus area.

This reflects the high prevalence of this chronic condition in China, where environmental factors and air quality contribute to an increasing number of asthma cases. The market dynamics around Allergic Rhinitis are also noteworthy, given that this condition affects a substantial portion of the population, driven by factors such as pollen and urban pollution.

These factors have become more pronounced in urban settings. Additionally, the market caters to Bronchospasm, which is frequently associated with respiratory disorders and requires effective management to improve patient quality of life.

Urticaria, though often less recognized than respiratory conditions, also represents an essential Application due to its impact on daily activities and overall well-being. The China Montelukast Intermediate Market segmentation reveals these Applications as integral components to healthcare solutions, fostering continuous growth and development in treatment methodologies.

With an emphasis on these specific Applications, market players have the opportunity to innovate and expand their product portfolios, addressing the unmet needs of patients and enhancing therapeutic outcomes. Furthermore, the market is supported by a robust healthcare system that encourages Research and Development initiatives.

This reflects China's commitment to improving public health and mapping out a pathway for future medications. Overall, the Application segment embodies an essential aspect of the Montelukast Intermediate Market in China, driven by a growing demand for effective treatments for asthma, allergic rhinitis, bronchospasm, and urticaria.

This is alongside supportive regulatory frameworks and increasing awareness among medical practitioners and patients alike. Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review.

Source: Primary Research, Secondary Research, _Market Research Future_ Database**,****and Analyst Review**

## **China Montelukast Intermediate Market Key Players and Competitive Insights**

The China Montelukast Intermediate Market has seen significant competition in recent years, largely driven by the increasing demand for effective asthma and allergy medications. Montelukast, a leukotriene receptor antagonist, plays a crucial role in the treatment of respiratory conditions, fostering a landscape where various manufacturers strive to enhance their market presence.

The sector is characterized by the ongoing efforts of key players to innovate and improve efficiency in production processes, alongside strategic partnerships and collaborations to stay competitive. Market players are also focusing on regulatory compliance and quality assurance, ensuring that their montelukast products meet international and domestic standards.

They are also adapting to the specific needs of the Chinese market. Huahai Pharmaceutical has emerged as a significant player in the China Montelukast Intermediate Market, leveraging its robust manufacturing capabilities and established distribution networks. The company boasts a strong commitment to research and development, which allows it to continually innovate and enhance its product lineup.

Huahai Pharmaceutical's strengths lie in its ability to maintain consistent quality and competitive pricing, which have helped it secure a loyal customer base across various segments of the market. Their focus on compliance with stringent regulatory requirements not only enhances their reputation but also facilitates smoother access to both domestic and international markets.

This strategic positioning has consequently enabled Huahai Pharmaceutical to efficiently address growing demands within the respiratory therapeutic segment in China. Zhejiang Jianfeng is another prominent player in the China Montelukast Intermediate Market. It is known for its specialized manufacturing processes and a strong portfolio of key products that include high-quality montelukast intermediates.

The company’s market presence is substantiated by its consistent investments in technology upgrades and quality control measures, ensuring that its offerings maintain high standards and meet the diverse needs of Chinese consumers. Zhejiang Jianfeng has established a competitive edge by securing strategic partnerships and pursuing mergers and acquisitions that strengthen its resource base.

This expands its operational capabilities within the region. This proactive approach, along with its dedication to sustainable practices and customer-oriented solutions, has positioned Zhejiang Jianfeng favorably within the rapidly evolving landscape of the Montelukast Intermediate Market in China.

### **Key Companies in the China Montelukast Intermediate Market Include**

## **China Montelukast Intermediate Market Industry Developments**

In recent months, the China Montelukast Intermediate Market has observed several significant developments and current affairs. Notably, companies like Huahai Pharmaceutical and Zhejiang Jianfeng have been expanding their production capacities in response to increased domestic and international demand for Montelukast.

In June 2023, Hubei Dongying announced an enhancement in their manufacturing processes to improve yield. In contrast, Jiangsu Hengrui is reportedly focusing on Research and Development to introduce a new generation of Montelukast products. There has also been an uptick in market valuation, driven by heightened competition among players such as Wuxi AppTec and Shijiazhuang Yiling, aimed at capturing a larger share of the growing asthma management segment.

No substantial mergers or acquisitions have been reported among the listed companies in the last few months. However, major happenings include the government's recent push for stringent quality regulations, which may reshape market dynamics. Over the past two to three years, the industry's consolidation trends have indicated a shift towards innovation and quality improvement.

This is especially true among leading firms like Hangzhou Jinchang and Nanjing Jianfeng, positioning them well for future growth potential in both domestic and international markets.

## **China Montelukast Intermediate Market Segmentation Insights**

### **Montelukast Intermediate Market Application Outlook**

## Market Drivers

### Growing Awareness of Preventive Healthcare

There is a notable shift towards preventive healthcare in China, which is impacting the montelukast intermediate market. As awareness of the importance of managing respiratory conditions early increases, more patients are seeking preventive treatments. This trend is reflected in the rising sales of montelukast, which is often prescribed as a preventive measure. The montelukast intermediate market is thus likely to experience growth as healthcare providers emphasize the importance of early intervention, leading to increased demand for intermediates used in the production of this medication.

### Increasing Prevalence of Allergic Conditions

The montelukast intermediate market in China is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis. Reports indicate that approximately 30% of the population suffers from some form of allergy, leading to a heightened demand for effective treatments. This trend is likely to drive the production and consumption of montelukast intermediates, as healthcare providers increasingly prescribe this medication to manage symptoms. The montelukast intermediate market is thus positioned to benefit from this growing patient population, as pharmaceutical companies expand their production capabilities to meet the rising demand.

### Government Initiatives for Healthcare Improvement

In China, government initiatives aimed at improving healthcare access and quality are positively influencing the montelukast intermediate market. The government has implemented policies to enhance the availability of essential medications, including those for respiratory conditions. This has resulted in increased funding for research and development in the pharmaceutical sector, particularly for montelukast intermediates. As a result, the montelukast intermediate market is likely to see a surge in investment, fostering innovation and potentially lowering production costs, which could enhance market competitiveness.

### Expansion of Pharmaceutical Manufacturing Capabilities

The montelukast intermediate market is benefiting from the expansion of pharmaceutical manufacturing capabilities in China. With advancements in production technologies and increased investment in manufacturing facilities, companies are better equipped to produce montelukast intermediates at scale. This expansion is crucial as it allows for greater efficiency and cost-effectiveness in production processes. Consequently, the montelukast intermediate market is poised for growth, as manufacturers can meet the rising demand for montelukast while maintaining competitive pricing.

### Rising Export Opportunities for Pharmaceutical Products

China's montelukast intermediate market is also influenced by rising export opportunities for pharmaceutical products. As the country strengthens its position in the global pharmaceutical supply chain, there is an increasing demand for montelukast intermediates from international markets. This trend is supported by favorable trade agreements and a growing reputation for quality in Chinese pharmaceuticals. The montelukast intermediate market is likely to capitalize on these opportunities, potentially leading to increased production and revenue as companies seek to expand their market reach.

## Future Outlook

The [Montelukast Intermediate Market](https://www.marketresearchfuture.com/reports/montelukast-intermediate-market-7887) is projected to grow at a 6.2% CAGR from 2025 to 2035, driven by increasing demand for asthma treatments and regulatory support.

**New opportunities:**

- Expansion of production facilities to enhance supply chain efficiency.
- Development of novel formulations to cater to diverse patient needs.
- Strategic partnerships with local pharmaceutical companies for market penetration.

By 2035, the montelukast intermediate market is expected to achieve robust growth and increased market share.

## Segment Insights

### By Application: Asthma Treatment (Largest) vs. Chronic Obstructive Pulmonary Disease (Fastest-Growing)

In the China montelukast intermediate market, the application segment is prominently characterized by asthma treatment, which holds a significant share of the market. This segment caters to a large patient population, driving a steady demand for medication. In addition to asthma, allergic rhinitis treatment also contributes notably, though it does not surpass the demand seen in asthma care. Chronic obstructive pulmonary disease, while currently less prevalent, is gaining attention as a growing segment due to increasing air pollution and smoking rates that lead to respiratory issues.

The growth trends in the application segment depict a dynamic landscape, with asthma treatment remaining the dominant player. However, the chronic obstructive pulmonary disease segment is emerging rapidly, driven by heightened awareness and diagnosis rates in urban populations. The rise in allergens and respiratory diseases further propels the market, suggesting that over the next several years, a significant shift may occur, resulting in an expanded share for the faster-growing segments like chronic obstructive pulmonary disease.

Asthma Treatment (Dominant) vs. Chronic Obstructive Pulmonary Disease (Emerging)

Asthma treatment is established as the dominant force in the application segment, characterized by strong market penetration and a loyal consumer base. The therapies available are well-accepted and continuously evolving to incorporate the latest advancements. On the other hand, chronic obstructive pulmonary disease is recognized as an emerging segment, gaining traction as awareness about the condition increases among healthcare providers and patients alike. The rapid urbanization and resultant environmental factors are contributing to a greater incidence of COPD, enhancing the demand for effective treatments. As more healthcare initiatives focus on respiratory illnesses, both segments are expected to co-exist, with asthma treatment remaining predominant while chronic obstructive pulmonary disease gradually captures a larger market share.

### By Formulation Type: Tablets (Largest) vs. Oral Solution (Fastest-Growing)

In the China montelukast intermediate market, the formulation type segment is characterized by a distribution where tablets hold the largest market share, benefiting from their widespread acceptance and convenience for patients. Granules and oral solutions represent vital options but to a lesser extent, reflecting specific patient needs and preferences. The demand dynamics among these formulations reveal that tablets dominate due to their ease of dose management, while oral solutions have seen increased attention due to their suitability for younger patients.

Growth trends in this segment are driven by several factors including rising healthcare awareness and changes in patient demographics. Tablets are expected to continue leading the market; however, oral solutions are on an upward trajectory as healthcare providers seek alternatives for patients with difficulty swallowing. Granules maintain a steady position but are primarily used in niche applications. Innovations in formulation technologies are also driving the segment's evolution, focusing on enhanced bioavailability and patient compliance.

Tablets (Dominant) vs. Granules (Emerging)

Tablets stand as the dominant formulation in the China montelukast intermediate market, largely due to their convenience and established presence among prescription medications. They offer precise dosing and cater to a wide demographic, including both adults and older children. In contrast, granules have emerged as a noteworthy alternative formulation, appealing particularly to specific patient groups such as pediatric patients who may struggle with swallowing pills. While tablets remain crucial for general market use, granules are increasingly recognized for their adaptability, allowing for customization in dosing and flavoring to improve adherence among younger populations. As patient-centric approaches gain traction, granules are likely to carve out a more defined space within the market.

### By Route of Administration: Oral (Largest) vs. Inhalation (Fastest-Growing)

In the China montelukast intermediate market, the Oral route of administration holds the largest share, predominantly due to its convenience and patient compliance. This method is favored by a significant portion of the population, benefiting from established usage patterns and the simplicity of administration. In contrast, Inhalation is emerging quickly, capturing attention for its efficiency and targeted delivery, appealing to specific patient needs, particularly among those suffering from respiratory issues.

The growth trends in this segment highlight an increasing shift towards Inhalation, driven by technological advancements and a growing emphasis on personalized medicine. As patients and healthcare providers prioritize treatments that maximize efficacy while minimizing systemic exposure, the Inhalation method has gained traction, reflecting its potential to become a dominant player in the future. The robust healthcare infrastructure in China further supports this evolution, allowing for the swift adoption of innovative delivery systems.

Oral (Dominant) vs. Inhalation (Emerging)

The Oral route of administration is characterized by its widespread acceptance and reliability, catering to a large demographic within the China montelukast intermediate market. This method benefits from easy storage and administration, reinforcing its position as the dominant choice for patients seeking convenience. Conversely, the Inhalation route is rapidly establishing itself as an emerging option, particularly for patients with acute respiratory conditions. It promises enhanced therapeutic effects through localized delivery and reduced systemic side effects. While still growing, this method's appeal lies in its innovative approaches to drug delivery, underscoring a shift towards more effective treatment options that meet diverse patient needs.

### By Distribution Channel: Pharmacies (Largest) vs. Online Pharmacies (Fastest-Growing)

In the China montelukast intermediate market, Pharmacies account for the largest share, serving as the primary distribution channel for consumers seeking montelukast. This channel dominates the market structure due to its extensive network and accessibility to patients, allowing for high volumes of dispensed medication. Meanwhile, Online Pharmacies have emerged as a competitive alternative, increasingly capturing a significant portion of the market as consumers lean towards the convenience of digital purchasing options. 

Growth trends indicate a shift towards Online Pharmacies, driven by technological advancements and changing consumer preferences. The rise of e-commerce has facilitated easier access to medicines and a broader range of available products, appealing especially to younger demographics. Pharmacies continue to thrive, but Online Pharmacies are fast becoming a favored channel due to the pandemic's lasting impact on shopping behavior, enhancing their market appeal.

Pharmacies (Dominant) vs. Online Pharmacies (Emerging)

Pharmacies have established themselves as the dominant distribution channel in the montelukast intermediate market by maintaining direct relationships with consumers and healthcare providers. They offer personalized services, contribute to patient adherence, and leverage their physical presence to enhance brand loyalty. Conversely, Online Pharmacies represent an emerging force, driven by the demand for convenience and the growing acceptance of online shopping for healthcare products. They are characterized by their ability to provide competitive pricing, home delivery, and a wide array of options, appealing to a tech-savvy population. As both segments continue to develop, their interplay will shape the future dynamics of the market.

## Competitive Benchmarking

The montelukast intermediate market exhibits a dynamic competitive landscape characterized by a blend of established players and emerging competitors. Key growth drivers include increasing demand for asthma and allergy medications, alongside a rising focus on cost-effective generic alternatives. Major companies such as Merck & Co. (US), Mylan N.V. (US), and Teva Pharmaceutical Industries Ltd. (IL) are strategically positioned to leverage their extensive research capabilities and established distribution networks. Merck & Co. (US) emphasizes innovation in drug formulation, while Mylan N.V. (US) focuses on expanding its generic portfolio to capture market share. Teva Pharmaceutical Industries Ltd. (IL) is enhancing its operational efficiency through digital transformation initiatives, collectively shaping a competitive environment that prioritizes both innovation and accessibility.In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain resilience. The market structure appears moderately fragmented, with several players vying for dominance. This fragmentation allows for competitive pricing strategies, yet the influence of key players remains substantial, as they set industry standards and drive technological advancements.

In October  Merck & Co. (US) announced a strategic partnership with a leading Chinese biotech firm to co-develop a new montelukast formulation aimed at improving patient compliance. This collaboration is likely to enhance Merck's market presence in China, tapping into local expertise and accelerating product development cycles. The strategic importance of this partnership lies in its potential to address specific regional needs while reinforcing Merck's commitment to innovation.

In September  Mylan N.V. (US) launched a new generic version of montelukast in China, significantly reducing the price point by approximately 15%. This move is indicative of Mylan's strategy to penetrate the market further by offering cost-effective solutions, thereby appealing to a broader patient demographic. The launch not only strengthens Mylan's competitive position but also reflects a growing trend towards affordability in the pharmaceutical sector.

In August  Teva Pharmaceutical Industries Ltd. (IL) expanded its manufacturing capabilities in China by investing $50 million in a new facility dedicated to the production of montelukast intermediates. This investment underscores Teva's commitment to enhancing supply chain reliability and meeting the increasing demand for its products in the region. The strategic importance of this expansion is multifaceted, as it not only boosts production capacity but also aligns with global sustainability goals by incorporating eco-friendly manufacturing practices.

As of November  current competitive trends are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming pivotal in shaping the landscape, as companies seek to enhance their capabilities and market reach. The shift from price-based competition to a focus on innovation, technology, and supply chain reliability is evident, suggesting that future differentiation will hinge on the ability to deliver high-quality, innovative solutions that meet evolving consumer needs.

## Recent News & Developments

In recent months, the China Montelukast Intermediate Market has observed several significant developments and current affairs. Notably, companies like Huahai Pharmaceutical and Zhejiang Jianfeng have been expanding their production capacities in response to increased domestic and international demand for Montelukast.

In June 2023, Hubei Dongying announced an enhancement in their manufacturing processes to improve yield. In contrast, Jiangsu Hengrui is reportedly focusing on Research and Development to introduce a new generation of Montelukast products. There has also been an uptick in market valuation, driven by heightened competition among players such as Wuxi AppTec and Shijiazhuang Yiling, aimed at capturing a larger share of the growing asthma management segment.

No substantial mergers or acquisitions have been reported among the listed companies in the last few months. However, major happenings include the government's recent push for stringent quality regulations, which may reshape market dynamics. Over the past two to three years, the industry's consolidation trends have indicated a shift towards innovation and quality improvement.

This is especially true among leading firms like Hangzhou Jinchang and Nanjing Jianfeng, positioning them well for future growth potential in both domestic and international markets.

## Report Scope

| MARKET SIZE 2024 | 32.0(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 33.98(USD Million) |
| MARKET SIZE 2035 | 62.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.2% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co. (US), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (IL), Aurobindo Pharma (IN), Cipla Ltd. (IN), Hikma Pharmaceuticals PLC (GB), Sandoz International GmbH (CH), Zydus Cadila (IN) |
| Segments Covered | Application, Formulation Type, Route of Administration, Distribution Channel |
| Key Market Opportunities | Emerging demand for montelukast intermediates driven by regulatory shifts and increased asthma prevalence. |
| Key Market Dynamics | Rising demand for montelukast intermediates driven by regulatory shifts and increased production capacity in local markets. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What was the overall market valuation of the China montelukast intermediate market in 2024?**
A: The overall market valuation was $32.0 Million in 2024.

**Q: What is the projected market valuation for the China montelukast intermediate market by 2035?**
A: The projected valuation for 2035 is $62.0 Million.

**Q: What is the expected CAGR for the China montelukast intermediate market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 6.2%.

**Q: Which companies are considered key players in the China montelukast intermediate market?**
A: Key players include Merck & Co., Mylan N.V., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma, Cipla Ltd., Hikma Pharmaceuticals PLC, Sandoz International GmbH, and Zydus Cadila.

**Q: What were the market values for asthma treatment in the China montelukast intermediate market in 2024?**
A: The market value for asthma treatment was $10.0 Million in 2024, projected to reach $20.0 Million by 2035.

**Q: How does the market for allergic rhinitis treatment compare to asthma treatment in the China montelukast intermediate market?**
A: The market for allergic rhinitis treatment was $12.0 Million in 2024 and is expected to grow to $24.0 Million by 2035, indicating a stronger growth trajectory than asthma treatment.

**Q: What are the different formulation types available in the China montelukast intermediate market?**
A: Formulation types include tablets, granules, and oral solutions, with tablets valued at $12.8 Million in 2024.

**Q: What distribution channels are utilized in the China montelukast intermediate market?**
A: Distribution channels include pharmacies, online pharmacies, and hospitals, with pharmacies valued at $12.8 Million in 2024.

**Q: What is the market value for the oral route of administration in the China montelukast intermediate market?**
A: The market value for the oral route of administration was $20.0 Million in 2024, projected to increase to $38.0 Million by 2035.

**Q: How do the market values for granules and oral solutions compare in the China montelukast intermediate market?**
A: Granules had a market value of $10.4 Million in 2024, while oral solutions were valued at $8.8 Million, indicating granules have a higher market presence.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-montelukast-intermediate-market-53056*